Return to Trial Database

QL05-37

Phase III, Double-Blind, Placebo-Controlled, Crossover Study Evaluating Aprepitant in Combination With a 5HT3 & Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-Based Chemotherapy Regimen

Status

Study Completed

Cancer Type(s)

Quality of Life

Study Contact

Publications

Phase III double blind placebo controlled crossover study evaluating a 5HT3 antagonist + dexamethasone +/- aprepitant in germ cell tumor patients receiving 5 day cisplatin combination chemotherapy

Randomized, Double-Blind, Placebo-Controlled, Phase III Cross-Over Study Evaluating the Oral Neurokinin-1 Antagonist Aprepitant in Combination With a 5HT3 Receptor Antagonist and Dexamethasone in Patients With Germ Cell Tumors Receiving 5-Day Cisplatin Combination Chemotherapy Regimens

Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer

Trial Locations

All sites in which the trial QL05-37 being conducted in.

No data was found